Open AccessExpression and correlation of MALAT1 and SOX9 in non‐small cell lung cancer
Author(s) -
Chen Wei,
Zhao Wei,
Chen Sheng,
Zhang Li,
Guo Zhongying,
Wang Lixin,
Wang Jipeng,
Wan Zongren,
Hong Yongqing,
Yu Liang
Publication year - 2018
Publication title -
the clinical respiratory journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.789
H-Index - 33
eISSN - 1752-699X
pISSN - 1752-6981
DOI - 10.1111/crj.12906
Subject(s) - malat1 , lung cancer , medicine , sox9 , stage (stratigraphy) , biomarker , immunohistochemistry , cancer research , real time polymerase chain reaction , adenocarcinoma , cancer , clinical significance , oncology , pathology , biology , long non coding rna , gene expression , downregulation and upregulation , gene , paleontology , biochemistry
Non‐small cell lung cancer (NSCLC) is the most common cause of cancer‐related deaths in the world. MALAT1 and SOX9 have important roles in tumour formation and development in several types of cancers. However, little is known about the function and co‐relationship of these 2 factors in NSCLC in vivo. Objectives To explore the role of MALAT1 and SOX9 expression relationship, their clinical pathological characteristics and OS on NSCLC patients. Methods Paired of primary lung cancer tissues and the matched tumour adjacent tissues were collected in 121 NSCLC patients. MALAT1 and SOX9 mRNA expression was measured by SYBR green q RT‐PCR assay. SOX‐9 protein expression was measured by streptavidin‐peroxidase (SP) staining method. Results MALAT1and SOX9 expression was higher in NSCLC tissues than the adjacent tissues, and they have positive correlation. Moreover, SOX9 protein expression was higher in NSCLC tissues, especially in MALAT1 mRNA higher expressed NSCLC tissues. MALAT1 and SOX9 mRNA expression were associated with age ( x 2 =11.474, P = .009), tumour size ( x 2 =26.839, P = .000), TNM stage ( x 2 =8.010, P = .046) and LEL. ( x 2 =53.908, P = .000). NSCLC patients with higher MALAT1 and SOX9 mRNA expression had poorer OS rates. Conclusions MALAT1 and SOX9 could be used as prognostic co‐biomarker in NSCLC.